Zynex (ZYXI) ROCE % : 1.88% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Zynex ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zynex's annualized ROCE % for the quarter that ended in Mar. 2024 was 1.88%.

Zynex ROCE % Historical Data

The historical data trend for Zynex's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex ROCE % Chart

Zynex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

67.59

23.90

25.94

22.00

12.79

Zynex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															7.28	15.45	15.63	7.35	1.88

Zynex ROCE % Calculation

Zynex's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	13.673	/	( ( (116.466 - 21.086)	+	(136.904 - 18.532) )	/ 2 )
	=	13.673	/	( (95.38	+	118.372)	/ 2 )
	=	13.673	/	106.876
	=	12.79 %

Zynex's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	2.1	/	( ( (136.904 - 18.532)	+	(126.225 - 21.755) )	/ 2 )
	=	2.1	/	( ( 118.372	+	104.47 )	/ 2 )
	=	2.1	/	111.421
	=	1.88 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Zynex (NAS:ZYXI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zynex ROCE % Related Terms

Thank you for viewing the detailed overview of Zynex's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zynex (ZYXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9555 Maroon Circle, Englewood, CO, USA, 80112

Website

https://www.zynex.com

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.

Executives

Daniel J Moorhead	officer: Chief Financial Officer	9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok	officer: See Remarks	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard	director, 10 percent owner, officer: President, CEO and Chairman	10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery	officer: See Remarks	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow	director	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress	director	3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc	10 percent owner	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea	officer: Chief Operating Officer	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112